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Abstract
Background: The p53 transcription factor is located at the core of a complex wiring of signaling pathways that are
critical for the preservation of cellular homeostasis. Only recently it has become clear that p53 regulates the
expression of several long intergenic noncoding RNAs (lincRNAs). However, relatively little is known about the role
that lincRNAs play in this pathway.
Results: Here we characterize a lincRNA named Pint (p53 induced noncoding transcript). We show that Pint is a
ubiquitously expressed lincRNA that is finely regulated by p53. In mouse cells, Pint promotes cell proliferation and
survival by regulating the expression of genes of the TGF-b, MAPK and p53 pathways. Pint is a nuclear lincRNA that
directly interacts with the Polycomb repressive complex 2 (PRC2), and is required for PRC2 targeting of specific
genes for H3K27 tri-methylation and repression. Furthermore, Pint functional activity is highly dependent on PRC2
expression. We have also identified Pint human ortholog (PINT), which presents suggestive analogies with the
murine lincRNA. PINT is similarly regulated by p53, and its expression significantly correlates with the same cellular
pathways as the mouse ortholog, including the p53 pathway. Interestingly, PINT is downregulated in colon primary
tumors, while its overexpression inhibits the proliferation of tumor cells, suggesting a possible role as tumor
suppressor.
Conclusions: Our results reveal a p53 autoregulatory negative mechanism where a lincRNA connects p53
activation with epigenetic silencing by PRC2. Additionally, we show analogies and differences between the murine
and human orthologs, identifying a novel tumor suppressor candidate lincRNA.
Keywords: lincRNA, non-coding RNA, p53, gene regulation, Polycomb repressive complex 2
Background
How cells coordinate and integrate information to pro-
duce adequate gene-expression output is still an unsolved
question with important implications for biology and
health. Even the slightest perturbation of cellular networks
can affect homeostasis and lead to cell transformation. Of
these cellular networks, the p53 pathway is possibly the
most relevant for preservation of cellular homeostasis. The
transcription factor p53 is located at the core of a complex
wiring of signaling pathways, and it has been proposed as
the master regulator of cell fate. The importance of the
tumor suppressing functions of p53 is shown by its high
mutation frequency in cancers and by the highly tumori-
genic phenotype of p53 null mice [1].
We and others have shown that long intergenic non-cod-
ing RNAs (lincRNAs) are part of the p53 transcriptional
network [2-4]. LincRNAs are intergenic transcripts longer
than 200 nucleotides that lack functional open reading
frames (ORFs). Although thousands of lincRNAs exist,
only a relatively small number have been studied in some
depth, indicating that lincRNAs have roles in numerous
physiological processes that involve gene regulation [5,6].
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cular scaffolds that hold and guide chromatin complexes
[7-9]. In particular, several lincRNAs have been found to
be associated with the Polycomb repressive complex 2
(PRC2) in a number of biological contexts, modulating
PRC2-specific targeting of genes [8,10,11]. PRC2 is com-
posed of three core components: Suppressor of zeste 12
(Suz12), Embryonic Ectoderm Development (EED), and
the H3K27 histone methyl transferase Enhancer of zeste
homolog 2 (Ezh2). PRC2 represses gene expression by cat-
alyzing H3K27 tri-methylation and modulating chromatin
structure [12], and is closely linked with the aberrant pro-
liferation of cancer cells. For instance, the Suz12 subunit is
overexpressed in colon and breast cancers [13], and Ezh2
is upregulated in a number of tumors, including Hodgkin
lymphoma, prostate cancer, and breast cancer [14,15].
Moreover, Ezh2 expression is associated with poor prog-
nosis, and is an indication of the metastatic potential of a
tumor [15,16]. Similarly, alterations in expression of lincR-
NAs in cancer have been reported, implicating lincRNAs
as possible attractive therapeutic targets [17,18].
In a previous work. we used mouse cell lines combined
with custom microarrays to monitor the differential
expression of lincRNAs, and found that p53 specifically
activated several lincRNAs. We characterized one of
them, lincRNA-p21, which was found to function as a
transcriptional repressor [3]. However, the contribution
of lincRNAs to p53 biology and to cancer still remains
largely unexplored.
Here, we expand this knowledge by characterizing Pint.
We show that Pint is a ubiquitously expressed mouse
lincRNA that is a direct p53 transcriptional target. Pint
acts as a positive regulator of cell proliferation and survi-
val, affecting the expression of hundreds of genes, includ-
ing a fraction of the p53 transcriptional network. PINT
interacts with PRC2 and is required for PRC2 targeting
of specific genes for H3K27 tri-methylation and repres-
sion. We also show that the PINT human ortholog is
similarly regulated by p53. Interestingly, whereas in nor-
mal tissue, PINT shows a significant inverse correlation
with the p53 pathway, it is downregulated in colorectal
cancer, and its enforced expression inhibits the prolifera-
tion of tumor cells. To our knowledge, the results pre-
sented here represent the first experimentally supported
connection between the p53 pathway and Polycomb epi-
genetic regulation mediated by a lincRNA. Moreover, the
data suggest that PINT may serve as a novel tumor
suppressor.
Results
Pint, a long non-coding RNA transcriptionally regulated
by p53
Despite p53 being one of the most studied biological
molecules, it has only recently become clear that p53
directly regulates numerous small and large non-coding
RNAs [2-4]. In addition, the nature of these transcripts
and the role that they play in this tumor suppressor path-
way remains relatively unexplored. By using custom tiling
microarrays, we previously identified multiple polyadeny-
lated non-coding transcripts that were induced upon
expression of p53 in mouse model systems [3]. In that
study, we showed that one of the most significantly
induced non-coding RNAs, previously named lincRNA-
Mkln1 (which from this point we refer to as Pint (p53-
induced non-coding transcript)), is generated from an
intergenic region located on chromosome 6 (Figure 1A;
see Additional file 1: Figure S1A). To investigate the regu-
lation of this genomic region by p53, we searched for p53
binding motifs using a method that scores genetic conser-
vation based on the evolutionary substitution pattern
inferred for the binding site locus [19]. We found three
putative p53 response elements (p53RE-1, p53RE-2, and
p53RE-3) inside this region with a high Pi LOD score
(>110) (Figure 1A; see Additional file 2).
To experimentally test the biological activity of these
regulatory elements, we first cloned the genomic regions
of p53RE-1, p53RE-2, and p53RE-3 into a reporter vector,
and transfected them into p53-reconstituted (p53
+/+)o r
non-reconstituted (p53
-/-)p 5 3
LSL/LSL mouse embryonic
fibroblasts (MEFs) to test the reporter-gene induction in
the presence or absence of p53. The tested sequences
were able to drive transcription of the reporter gene in the
presence but not in the absence of p53, with the transcrip-
tional induction being even higher when the p53
+/+ cells
were treated with the DNA-damaging drug doxorubicin
(Figure 1B).
Next, to verify the activity of the p53REs in Pint locus,
we performed p53 chromatin immunoprecipitation
(ChIP), which showed specific and robust binding of p53
to all three predicted p53REs in the endogenous locus
upon doxorubicin-induced DNA damage in p53
+/+,b u t
not p53
-/- cells (Figure 1C).
To further confirm our observations, we analyzed pre-
viously published p53 ChIP sequencing (ChIP-seq) data
from mouse embryonic stem cells (mESCs) (total and
phosphorylated p53) [20] and MEFs (total p53) [21]. In
mESCs, we identified ChIP-seq peaks of total and phos-
phorylated p53 after doxorubicin treatment at positions
corresponding to Pint p53RE-1 and p53RE-2, but not at
the position corresponding to p53RE-3 (see Additional file
1, Figure S1), suggesting that p53RE-3 activity may be cell
type-dependent. The previously published p53 ChIP-seq
data from MEFs showed specific peaks at the Pint p53RE-1,
p53RE-2, and p53RE-3 locations in doxorubicin p53 wild-
type but not p53-null MEFs, in agreement with our results
( F i g u r e1 D ) .T o g e t h e r ,t h e s ed a t ac o n f i r mt h a tt h ePint
genomic locus is controlled by p53, which directly binds to
the harbored regulatory sequences.
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Figure 1 Pint is a p53-regulated long intergenic non-coding RNA (lincRNA). (A) Schematic representation of the Pint genomic locus. Asterisks
represent p53 response elements (p53REs). (B) Relative firefly luciferase expression driven by genomic sequences containing p53REs in p53-restored
p53
LSL/LSL (p53
+/+)o rp 5 3
LSL/LSL (p53
-/-) cells treated with doxorubicin. Values were normalized by Renilla levels and are the mean ± standard deviation
(SD) of three biological replicates. Asterisks represent significant differences determined by t-test relative to the same plasmid transfected in
doxorubicin (DOX)-treated p53
-/-. (C) Effect on Pint p53RE-1, p53RE-2, and p53RE-3, Cdkn1a p53RE, or an irrelevant region (control) of p53 chromatin
immunoprecipitation (ChIP) enrichment in p53-restored p53
LSL/LSL (p53
+/+)o rp 5 3
LSL/LSL (p53
-/-) cells treated with doxorubicin (+DOX) or left untreated
(-DOX). Enrichment values are relative to input and the mean ± SD of three biological replicates. Asterisks represent statistical significant differences
from the control as determined by t-test (*P<0.05, **P<0.01). (D) (Top) p53 ChIP sequencing (ChIP-seq) peaks from mouse embryonic fibroblasts (MEFs)
treated with doxorubicin [21]. Positions of p53REs are indicated by red asterisks. (Bottom) Pint variants identified by 5’ and 3’ rapid amplification of
cDNA ends (RACE) cloning. (E) Pint levels detected by quantitative real time RT-qPCR in p53-restored p53
LSL/LSL (p53
+/+)o rp 5 3
LSL/LSL (p53
-/-)c e l l s
treated with 150 nM doxorubicin (+DOX) or left untreated (-DOX) for the indicated time (values represent the mean ± SD of three biological replicates,
and asterisks represent significant differences of Pint level at 48 hours relative to the doxorubicin-treated p53
-/- cells). (F,G) Pint levels at different times
after p53 restoration in (F) lung tumor (G) and sarcoma cell lines. Values are the mean ± SD of four replicates.
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scripts produced in this p53-regulated locus, we carried
out 5’ and 3’ rapid amplification of cDNA ends (RACE)
cloning from doxorubicin-treated MEFs. We detected a
transcript of 1157 nucleotides and 4 exons, similar to the
annotated EST BC145649, isoform that we named Pint A.
Additionally, we cloned two shorter transcripts of 516
(Pint B)a n d6 5 9( Pint C) nucleotides, which share three
and two exons, respectively, with the longer Pint A variant
(Figure 1D; see Additional file 1: Figure S2A).
To obtain additional information on Pint transcript
structure, we analyzed publicly available RNA-seq data
from mouse heart, thymus, and small intestine by using
the Cufflinks method for transcript assembly (see Addi-
tional file 1: supplementary methods). This analysis pre-
dicted six different RNA isoforms in this region, two of
which correspond to Pint A and Pint B variants (see
Additional file 1: Figure S2A). Pint C was not detected by
the RNA-seq analysis, which could be due to the different
cell type used for RACE cloning. Interestingly, one of the
experimentally validated p53REs (p53RE-1), is located at
the 5’ end of all detected transcripts, in agreement with
the transcriptional activation of these response elements
by p53 (see Additional file 1: Figure S2A). The other two
p53 sites (p53RE-2 and p53RE-3) are respectively 100,000
and 120,000 bp further downstream (Figure 1D). Addi-
tionally, ChIP-seq data from MEFs showed that p53RE-1
overlaps with a peak for H3K4me3, the chromatin mark
associated with active promoters, while p53RE-2 and
p53RE-3 are also enriched in H3K4me1 (see Additional
file 1: Figure S2A), suggesting that the two distal sites
could act as enhancers.
Next, to characterize the non-coding nature of the
cloned RNAs, we analyzed the coding potential across all
full-length isoforms identified. All the potential ORFs
found in the transcripts are small (< 100 amino acids) and
do not contain evolutionary conserved codons (Codon
Substitution Frequencies scores < -205), strongly suggest-
ing a lack of protein-coding capacity [22].
We focused our studies on variant Pint A (1157 nt),
which is the longest of the cloned isoforms and the one
with the highest expression level (see Additional file 1,
Figure S2B). Analysis of Pint A expression across a panel
of normal mouse tissues showed that it is ubiquitously
expressed (see Additional file 1: Figure S2C).
We next tested the expression of Pint in different mouse
cell types at different time points after induction of p53 by
doxorubicin-induced DNA damage, including p53
+/+ and
p53
-/- MEFs (Figure 1E), and K-RAS lung tumor and sar-
coma cells (Figure 1F,G; see Additional file 1: Figure S2D)
after genetic restoration of the p53 gene [23]. In all cell
lines tested, levels of Pint increased significantly in a tem-
poral manner upon p53 induction.
N e x t ,t of u r t h e rc o n f i r mt h er e g u l a t i o no fPint by p53,
we depleted p53 by small interfering RNA (siRNA) treat-
ment in p53-restored p53
LSL/LSL MEFs (which are func-
tionally equivalent to p53
+/+ MEFs [23]), and transfected a
non-targeting siRNA as control. Inhibition of p53 resulted
in a decrease of Pint levels, whereas the control siRNA
had no effect (see Additional file 1: Figure S2B). We there-
fore conclude that Pint expression is induced in a p53-
dependent manner.
Collectively, our results show that Pint is a ubiquitously
expressed lincRNA, which has several isoforms and is
transcriptionally regulated by p53.
Pint modulates cell survival and proliferation
To elucidate the biological role of Pint, we attempted to
perform RNA interference (RNAi)-mediated loss of
function studies. To that end, we designed multiple Pint-
targeting siRNAs and short hairpin RNAs (shRNAs), and
transfected or transduced cells to deplete the lincRNA
levels. However, these strategies were unsuccessful in
lowering the levels of Pint (data not shown), which
prompted us to use an alternative approach.
We then designed anti-sense oligonucleotides (ASOs)
with special modifications to target Pint for degradation
by RNaseH [24]. By independently transfecting two differ-
ent Pint-targeting ASOs we were able to obtain a signifi-
cant decrease (>75%) in Pint levels compared with
transfections using two independent control ASOs or in
the absence of oligo transfection (PBS) (Figure 2A; see
Additional file 1: Figure S3A). Interestingly, we were able
to deplete all three Pint isoforms (data not shown), sup-
porting the notion that the inhibition by ASOs occurs at
the level of pre-spliced RNA [25].
Next, to assess the effect of Pint downregulation, we
treated p53-restored p53
LSL/LSL MEFs with two indepen-
dent Pint-targeting ASOs or with two independent con-
trol ASOs, and monitored cell proliferation at 24 and 48
hours after transfection, while treating the cells with
doxorubicin to induce the p53 response (Figure 2B).
There was a significant decrease in proliferation of cells
depleted of Pint by the two specific ASOs compared
with the cells treated with either of the two ASO con-
trols or compared with the untransfected cells (Figure 2B).
Conversely, when Pint (isoform A) was transiently overex-
pressed using a plasmid under the control of a cytomega-
lovirus promoter (Figure 2C), cell proliferation was
increased compared with the cells transfected with the
empty plasmid (Figure 2D). Similarly, stable overexpres-
sion of Pint by retroviral infection had a positive effect on
cell proliferation rate (data not shown). Interestingly, we
also found a slight effect on proliferation after Pint deple-
tion and overexpression in the absence of doxorubicin-
induced DNA damage, although this was not as significant
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Figure 2 PINT modulates cell proliferation and apoptosis. (A) Inhibition of Pint. Pint levels were detected by quantitative real time (RT-qPCR) in
p53-restored doxorubicin-treated p53
LSL/LSL MEFs 36 hours after transfection with two Pint-specific anti-sense oligonucleotides (ASOs) (ASO1 and
ASO2), two control ASOs (control ASO -1 and -2), or a blank (PBS) control, and 12 hours of doxorubicin treatment. Values normalized to Gapdh and are
the mean ± SD of three replicates. (B) Pint positively regulates cell proliferation. Relative number of p53-restored p53
LSL/LSL mouse embryonic
fibroblasts (MEFs) transfected with ASOs for Pint inhibition, and treated with doxorubicin from 24 h post-transfection. Cell numbers are determined by
MTS assay. Values are mean ± SD of three replicates. (C) Overexpression of Pint. Pint levels where measured like in (A) in p53-restored doxorubicin-
treated p53
LSL/LSL MEFs 36 hours after transfection and 12 hours of doxorubicin treatment with Pint A isoform expressing plasmid or an empty plasmid
as control. (D) Pint positively regulates cell proliferation. Cells were transfected as in (C) and treated with doxorubicin from 24 hours post-transfection.
(E,F). Negative effect of Pint on apoptosis induction. Apoptosis levels were determined by quantification of caspase 3/7 levels after (E) inhibition or
(F) overexpression of Pint in p53-restored p53
LSL/LSL MEFs treated with doxorubicin. Values are the mean ± SD of three replicates. (G,H).E f f e c to fPint
on cell cycle regulation. Relative cell numbers in each cell cycle phase were determined by fluorescence-activated cell sorting (FACS) of
bromodeoxyuridine (BrdU) incorporation and propidium iodide (PI) staining of p53-restored p53
LSL/LSL MEFs treated as in (A) or (C). Percentages of
cells in each phase are represented and values are the mean ± SD of three replicates.
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Figure S3B,C). We thus concluded that Pint is a positive
regulator of cell proliferation.
To determine how cell proliferation is modulated by
Pint, we investigated different aspects of the cellular pheno-
type. When Pint was depleted and cells were treated with
doxorubicin to induce DNA damage, there was a signifi-
cant increase in the number of apoptotic cells (Figure 2E).
Consistent with these results, Pint overexpression resulted
in the opposite phenotype, decreasing cellular apoptosis
(Figure 2F). There was also a slight but significant effect on
cell cycle regulation. Transfection of the specific Pint-tar-
geting ASOs caused a decrease in the fraction of S-phase
cells and a concomitant increase in the fraction of cells in
G1 (Figure 2G), whereas Pint overexpression caused the
opposite effect (Figure 2H). These data suggest that, under
DNA-damaging conditions, Pint affects both induction of
apoptosis and regulation of the cell cycle.
Next, to determine whether the aforementioned effects
were cell type-specific, we performed similar experiments
in the mouse lung tumor cell line LKR [3]. There was a
significant decrease in cell proliferation following Pint
depletion in these cells by doxorubicin-induced DNA
damage (see Additional file 1: Figure S3D,E), whereas
lincRNA overexpression caused the opposite effect (see
Additional file 1: Figure S3F,G). Inhibition of Pint in dox-
orubicin-treated 3T3 cells caused a similar effect on cell
proliferation and apoptosis induction (see Additional file
1: Figure S3H to K). Furthermore, depletion of Pint in
these cells affected their ability to grow independently of
attachment and to form colonies independently of cell-cell
contact (see Additional file 1: Figure S3L,M), opposite to
the effect caused by Pint overexpression (see Additional
file 1: Figure S3N).
We therefore concluded that Pint positively regulates
cell viability and proliferation at different levels, including
induction of cellular apoptosis and regulation of the cell
cycle, both in the presence and absence of DNA damage.
Pint regulates the expression of genes involved in cell
proliferation and survival, including genes of the p53
pathway
Given the role of Pint in cell survival and proliferation,
we wanted to investigate the effect of the lincRNA on
gene expression. We transfected p53-restored p53
LSL/LSL
MEFs with a pool of ASOs to deplete Pint expression or
with a non-targeting ASO as control, then treated the
cells with doxorubicin to induce DNA damage, and
extracted total RNA for microarray analysis in triplicate.
We identified 947 genes affected by lincRNA inhibition
(B > 3) (see Additional file 1,: Figure S4A; see Additional
file 3). Gene Ontology analysis of these genes identified
significant enrichment in pathways relevant for signaling,
proliferation, and survival, including extracellular matrix
(ECM)-receptor interaction and transforming growth fac-
tor (TGF)-b, mitogen-activated protein kinase (MAPK),
or p53 signaling pathways (Figure 3A; see Additional file
3). In agreement with this observation, the most signifi-
cant biological functions of Pint-regulated genes included
cancer, cellular movement, cellular growth and prolifera-
tion, cell death and survival, and organism development
(see Additional file 1: Figure S4B).
To independently validate the microarray findings, cells
were transfected with two different Pint-targeting ASOs or
two control ASOs, and the levels of 15 mRNAs were deter-
mined by quantitative real time (RT-qPCR). This experi-
mental validation confirmed the microarray results for 14
of 15 genes (93%), including the downregulation of Tgfb1,
Serpina3n, Nkx2-9,a n dIl1r1,a n du p r e g u l a t i o no fGadd45b
and Egr2, among others (see Additional file 1, Figure S4C).
Interestingly, genes affected by Pint inhibition did not
include any of the six neighboring genes located 250 kb
upstream or downstream of the Pint locus. Furthermore,
upon Pint depletion, we did not observe any change in
the levels of the microRNA mir29a/b, encoded down-
stream of Pint, which we determined by RT-qPCR on the
small RNA fraction of cells (data not shown). Therefore,
our data suggest that although Pint depletion affects the
expression of hundreds of genes, Pint does not act on
genes that are proximally located to it.
The direct transcriptional regulation of Pint by p53
strongly suggests a functional relationship between the
two. This relationship was confirmed by the presence of
the p53 pathway as one of the cellular pathways most
affected by Pint inhibition (Figure 3A). Moreover, the
microarray data analysis predicted p53 as one of the
upstream regulators of genes affected by Pint (B > 5, P =
4.20 × 10
-13) (Figure 3B; see Additional file 4).
To further explore the relationship between Pint and
p53, we treated cells with p53 siRNA or a control siRNA,
and subjected the extracted RNA to microarray analyses
(Figure 3C). As expected, the analyses showed that hun-
dreds of genes were affected by p53 depletion (1,146 genes,
B > 3), including most of the well-known p53 target genes
such as Cdkn1A, Fas,a n dPerp (see Additional file 5).
Next, to detect genes co-regulated by p53 and Pint,w e
compared the genes affected by p53 depletion with those
affected by Pint depletion. Interestingly, a significant sub-
set of the genes affected by Pint inhibition was similarly
affected by p53 inhibition (86 genes, B > 3, P = 1.5 × 10
-5)
(Figure 3A,D). These genes were enriched in functional
terms that include cellular apoptosis and cell cycle regula-
tion (Figure 3A), and secondary targets of p53, such as
Ikbke, Dgka, Adam8,a n dSerpine2 (see Additional file 6).
These results confirmed that Pint gene regulation com-
prises part of the p53 transcriptional response.
In addition to the transcription factor p53, other
upstream regulators are predicted for Pint-regulated
Marín-Béjar et al. Genome Biology 2013, 14:R104
http://genomebiology.com/2013/14/9/R104
Page 6 of 17genes, including the cytokine tumor necrosis factor a, the
transcription regulator nuclear factor B1A or the tumor
growth factor -b1 (see Additional file 4). We therefore
investigated the genes that are regulated by Pint but not
p53. The most significant biological functions of the genes
regulated specifically by Pint include cell death, response
to hypoxia, and vasculogenesis (see Additional file 1:
Figure S4D). By contrast, the top biological functions of
the genes regulated by p53 but not Pint are segregation of
chromosomes, mitosis, and cell cycle progression (see
Additional file 1: Figure S4E). These results confirm that
Pint is involved in biological processes related to survival
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Page 7 of 17and invasion, which are different from those of the p53
core response. In addition, the Pint-independent compo-
nent of the p53 pathway is clearly enriched in cell cycle
regulatory genes.
Taken together, our data strongly suggest that Pint plays
an important role in gene regulation via a trans-mediated
mechanism, modulating cellular pathways that are crucial
for cell survival and proliferation, including genes of the
p53 pathway.
Pint, a nuclear RNA that interacts with Polycomb
repressive complex 2
We next investigated the mechanism by which Pint regu-
lates gene expression. We first analyzed the subcellular
localization of Pint by RT-qPCR in nuclear versus cyto-
plasmic fractions, and found that at least 80% of the Pint
RNA was present in the cell nucleus (Figure 4A). We
further confirmed this observation by single-molecule
RNA fluorescence in situ hybridization (FISH) to detect
individual molecules of Pint in 3T3 MEFs. The analysis
showed that more than 85% of the PINT foci were pre-
sent in the cell nucleus (Figure 4B,C).
Because many lincRNAs have been found to be asso-
ciated with nuclear protein complexes [7,8,10], we hypothe-
s i z e dt h a tt h i sc o u l db et h ec a s ef o rPint. Interestingly, a
transcript that we found to correspond to Pint was pre-
viously identified in a genome-wide screen by RNA immu-
noprecipitation sequencing (RIP-seq) for PRC2-interacting
RNAs in mouse embryonic stem cells [26]. Moreover, ana-
lysis of the Pint A sequence revealed the presence of 10
Ezh2-interacting motifs [27], a larger number than would
be expected by chance (P < 0.05). Therefore, we decided to
test the interaction between Pint and PRC2.
To do so, we performed crosslinking followed by RIP in
doxorubicin-treated MEFs using an antibody specific for
the Suz12 subunit of PRC2 or, as control, an antibody
against WD repeat domain 5 (Wdr5), a protein associated
w i t ht h em i x e dl i n e a g el e u k e mia (MLL) chromatin acti-
vator complex. We found a highly significant enrichment
of Pint in PRC2 immunoprecipitates, whereas no Pint
enrichment was seen with the Wdr5 antibody or control
IgG (Figure 4D).
To further confirm the interaction between Pint and
PRC2, we carried out RNA pulldown experiments using in
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extracts of doxorubicin-treated MEFs. Pint was able to
pull down PRC2, as detected by western blotting using an
anti-Suz12 antibody, whereas only negligible levels of
Suz12 were bound by the anti-sense RNA sequence used
as control (Figure 4E).
In addition, to determine whether the interaction
between Pint and PRC2 was direct or mediated by other
factors, we performed RNA pulldown experiments with in
vitro biotinylated Pint RNA and purified PRC2. We found
that Pint was able to interact with the recombinant puri-
fied PRC2, unlike the control RNA (Figure 4F), suggesting
that Pint directly binds to PRC2.
In conclusion, our data show that Pint is mainly loca-
lized to the cell nucleus, and directly interacts with PRC2.
Pint affects gene expression by regulating PRC2
occupancy of specific genes for repression
Several studies suggest that the association of lincRNAs
with chromatin complexes such as PRC2 provides regula-
tory specificity to the complexes by localizing them to
genomic DNA targets [3,10,11,28-30]. We therefore
hypothesized that Pint may act by regulating the binding
of PRC2 to certain genomic loci for their repression. Con-
sistent with this hypothesis, we found that a significant
number of the genes regulated by Pint (141 genes, P = 1.4
×1 0
-7) had been previously reported [31] as bound by
PRC2 in mESCs (Figure 5A; see Additional file 7). In
agreement with this observation, we found this subset of
Pint-regulated genes to be enriched in H3K27 tri-methyla-
tion around their transcriptional start site, whereas the
remaining Pint -regulated genes showed low H3K27me3
but high H3K4me3 levels (Figure 5B; see Additional file 1:
Figure S5A). Interestingly, pathway analysis of these genes
identified enrichment in MAPK signaling, ECM-receptor
interaction, and TGF-b signaling, consistent with these
pathways being affected by Pint inhibition (see Additional
file 1: Figures S5B and S3A). Furthermore, the most signifi-
cant biological function of this gene subset is cellular
growth and proliferation (Figure 5C).
Next, to further test our hypothesis of Pint requirement
for PRC2 targeting, we proceeded as follows. We ran-
domly selected a group of 15 genes that (i) we found to
be de-repressed by inhibition of Pint in p53-restored
p53
LSL/LSL MEFs (see Additional file 3; see Additional file
1: Figure S5C), and (ii) have been reported as regulated
by H3K27me3 in MEFs [32]. We reasoned that these
genes might be co-regulated by PRC2 and Pint. We then
determined the association of PRC2 with these genes by
Suz12 ChIP-qPCR in p53-restored p53
LSL/LSL MEFs, with
or without inhibition of Pint (Figure 5D). The ChIP
results confirmed that Suz12 occupied all the analyzed
genes in the control conditions (see Additional file 1:
Figure S5D). Interestingly, the binding of Suz12 to 12 of
these loci (80%) was significantly decreased upon Pint
depletion (Figure 5D; see Additional file 1: Figure S5D),
correlating with an increase in their expression (see
Additional file 1: Figure S5C). However, there was no
change in Suz12 occupancy of genes that are bound by
Suz12 but whose expression was unaffected by Pint
knockdown (Figure 5D, controls; see Additional file 1:
Figures S5C, D).
Similarly, we performed ChIP to determine the level of
H3K27me3 at these gene promoters under the same
experimental conditions. Correlating with the loss of PRC2
binding, there was a significant decrease in H3K27me3
levels in 11 of the 15 (73%) analyzed regions when Pint
was inhibited (Figure 5E; see Additional file 1: Figure S5E),
whereas there were no significant changes at the control
genes. Interestingly, in some cases, the changes in
H3K27me3 were not as pronounced as the loss of Suz12
binding, probably because of the need for cell division and/
or histone demethylase activity to erase the histone mark.
We therefore conclude that Pint is required for PRC2
targeting to these genes, which in turn affects their
H3K27 methylation levels and expression.
We speculated that if regulation by Pint is mediated by
its interaction with PRC2, the effect of Pint in cell prolif-
eration should be strongly dependent upon PRC2 pre-
sence. To test this hypothesis, we generated 3T3 MEFs
with stable knockdown of the Ezh2 subunit of PRC2,
using shRNA lentiviral transduction, and, as control, we
transduced 3T3 MEFs with a non-targeting shRNA. The
Ezh2 shRNA stable cell line showed a decrease of around
60% in Ezh2 protein levels compared with the shRNA
control cell line (see Additional file 1: Figure S5F).
Next, we transfected both cell lines with a pool of
ASOs to deplete Pint levels, or with a control ASO (see
Additional file 1: Figure S5G,H), and determined their
proliferation rate. The proliferation of control cells was
negatively affected by Pint inhibition (Figure 5F), and
interestingly, arrest of proliferation was strongly
enhanced when both Pint and Ezh2 were depleted in the
cells (Figure 5G). In parallel, both cell lines were trans-
fected with a plasmid overexpressing Pint or a control
plasmid, and their proliferation rate was determined.
Although Pint overexpression induced proliferation of
the control cells, it had no effect on the Ezh2-depleted
cells (Figure 5F,G). These results suggest that the biologi-
cal function of Pint requires PRC2, indicating a func-
tional relationship between Pint and Ezh2.
Taken together, these data indicate that Pint is required
for the targeting of PRC2 to some genes for repression,
which in turn affects the proliferative state of the cells.
Human PINT is a putative tumor suppressor lincRNA
The role that Pint plays in gene regulation and in the p53
tumor suppressor pathway motivated us to explore
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Page 9 of 17whether a Pint human ortholog exists. We found that the
PINT human syntenic genomic region in chromosome 7
also encodes a non-coding RNA annotated as FLJ43663.
Comparison of human and mouse sequences identified
that the highest homology between the two lincRNAs
resides at the 5’ end of their sequences (see Additional
file 1: Figure S6A,B). We therefore hypothesized that,
similarly to mouse Pint, human PINT is regulated by p53.
To test this, we first analyzed the expression of PINT by
qRT-PCR in p53
+/+ and p53
-/- matched HCT116 human
colorectal cancer cell lines [33], and found that PINT was
induced in p53
+/+,b u tn o tp 5 3
-/- cells when treated with
the DNA-damaging drug 5-fluorouracil (5-FU) (Figure 6A,
B). Next, to determine the functionality of the three con-
served p53REs identified in the mouse and human PINT
(see Additional file 2), we performed p53 ChIP on the
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Page 10 of 17human cells. The p53 protein was found to bind to the
three human p53REs upon doxorubicin-induced DNA
damage, but not in the absence of treatment (Figure 6C).
As control, we also included p53
-/- cells, in which we did
not detect any p53 ChIP enrichment (Figure 6C).
To further confirm the regulation of PINT by p53, we
cloned the human genomic sequences harboring each of
the three p53REs into a plasmid containing a reporter
gene. The three sequences were able to induce expression
of the reporter gene when transfected into p53 wild-type,
but not p53-null cells (Figure 6D).
Together, our data indicate that PINT is a bona fide p53
transcriptional target, with conserved regulation across
mammalian species.
Given the crucial role that p53 plays in cancer, we
speculated that PINT expression might be altered in pri-
mary tumors. To test this hypothesis, we analyzed PINT
levels in tumor tissue and matched normal tissue samples
from 14 surgical patients with colorectal cancer (stages I
to III) (see Additional file 8). Intriguingly, we found a sig-
nificant (P < 0.01) downregulation of PINT in colorectal
tumors compared with normal tissue (Figure 6E), suggest-
ing a potential role of the lincRNA as a tumor suppressor.
To explore this hypothesis, we investigated in more
detail the role of PINT in human cells. We first stably
overexpressed PINT in the HCT116 colon cancer cell line
by retroviral infection (see Additional file 1: Figure S6C)
and assessed the proliferation rate. Interestingly, cells over-
expressing PINT showed a significant decrease in their
growth rate compared with the control cells in either the
presence or absence of doxorubicin-induced DNA damage
(Figure 7A,B). This decrease in proliferation was confirmed
by the cell cycle profile analysis. Compared with control
cells, PINT -overexpressing cells had a lower percentage of
cells in S phase in the absence of doxorubicin-induced
DNA damage (Figure 7C), whereas upon doxorubicin
treatment, PINT-overexpressing cells showed more pro-
nounced cell cycle arrest, appearing as a significantly lower
number of cells in S phase and higher number in G1/0
and G2/M phases (Figure 7C). Subsequently, we quantified
the apoptosis levels in these stable cell lines, and found
increased apoptosis when PINT was overexpressed both in
t h ep r e s e n c ea n da b s e n c eo fd o x o r u b i c i n - i n d u c e dD N A
damage (Figure 7D). We concluded that PINT has a nega-
tive effect on proliferation and survival of HCT116 cells.
Next, to test whether the observed effects of PINT
overexpression are specific to HCT116 cells, we gener-
ated a stably PINT-overexpressing A549 lung adenocar-
cinoma cell line (see Additional file 1: Figure S6D), and
subjected the cells to similar analyses, determining their
proliferation rate, cell cycle profile, and apoptosis levels.
Overexpression of PINT in A549 cells caused decreased
proliferation (Figure 7E,F) with an increased number of
cells arrested in G2/M phases, both in the presence and
absence of doxorubicin-induced DNA damage, but being
more pronounced with doxorubicin treatment (Figure 7G)
Similarly, enforced PINT expression in A549 cells resulted
in increased apoptosis, both in the presence and absence
of doxorubicin treatment (Figure 7H). Together, these
results indicate that PINT is a negative regulator of cell
proliferation and apoptosis of tumor cells, which is consis-
tent with a role as a tumor suppressor lincRNA.
Next, to obtain further insight into the role of PINT,w e
determined the biological pathways that are associated
with PINT expression in normal tissues, where it has
higher expression. To that end, we obtained gene-expres-
sion data from microarrays performed on 23 samples from
normal colon (n =1 4 )a n dr e c t u m( n =8 ) ,a n dan o r m a l
colon cell line. The microarrays contained 60,000 probes
designed to detect the expression of 27,958 protein-coding
genes and 7,419 non-coding RNAs. We selected expres-
sion data from nine probes corresponding to PINT,a n d
computed the correlation existing between these and the
expression of mRNAs grouped in KEGG (Kyoto Encyclo-
pedia of Genes and Genomes) pathways [34]. The analysis
showed that PINT expression had a significant positive
(r > 0.5, n = 23, p < 0.05) or negative (r < -0.5, n =2 3p <
0.05) correlation with a number of pathways similar to
those regulated by its mouse ortholog, including the
MAPK, Wnt, and TGF-b pathways (positive correlations).
and p53, apoptosis, and peroxisome proliferator-activated
receptor signaling (negative correlations) (Figure 7I). Thus,
our data suggest that PINT expression and regulation are
conserved between mouse and human. However, their
function results in different biological outcomes, possibly
reflecting species-specific aspects of cellular pathways.
Collectively, our results show that PINT is a lincRNA
specifically regulated by p53 in mouse and human cells.
In mouse cells, PINT promotes proliferation and survival,
and functions by regulating targeting of PRC2 to specific
genes for repression. The human ortholog, PINT,i sa l s o
transcriptionally regulated by p53, and its expression cor-
relates with similar cellular pathways to those of the
mouse lincRNA. However, in contrast to the mouse Pint,
human PINT is a negative regulator of proliferation and
survival, and is downregulated in colon cancer, represent-
ing a novel tumor suppressor candidate lincRNA.
Discussion
Although thousands of lincRNAs have been identified in
mammalian cells, understanding of lincRNA biology and
role in disease remains relatively poor. A common feature
of lincRNAs is their fine transcriptional regulation [35,36],
which may be key to their specific regulatory roles. The
transcription factor p53 has been subjected to thorough
scrutiny over the years because of its relevance in cellular
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Figure 7 Human PINT inhibits tumor cell growth. (A.B). Relative number of PINT-overexpressing HCT116 cells (PINT)o rc o n t r o lc e l l s( v e c t o r )
that were (A) left untreated or (B) treated with 500 nM doxorubicin (DOX), as determined by MTS assay. (C) Relative number of cells of HCT116
stable cell lines in each phase of the cell cycle. Cells were treated as for (A) and (B) for 12 hours, and cell cycle phases were determined by
fluorescence-activated cell sorting (FACS) of bromodeoxyuridine (BrdU) incorporation and propidium iodide (PI) staining. (D) Percentage of
apoptotic cells in HCT116 stable cell lines treated as in (C), determined by quantification of annexin V-positive cells. (E,F). Relative number of
PINT-overexpressing A549 cells (PINT) or control cells (vector) that were (E) left untreated or were treated with 500 nM doxorubicin (F), as
determined by MTS assay. (G) Relative number of A549 stable cell lines in each phase of the cell cycle determined as in (C). (H) Relative number
of cells of A549 stable cell lines undergoing apoptosis, determined as in (D). (I) Correlation of PINT with KEGG (Kyoto Encyclopedia of Genes and
Genomes) pathways. Significant correlation coefficients between the indicated cellular pathways and PINT microarray probes.
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Page 13 of 17homeostasis, but only recently have researchers realized
that lincRNAs are an active part of the p53 transcriptional
network. Among them is lincRNA-p21, which functions as
a transcriptional gene repressor in mouse cells [3], and
PANDA, which regulates the expression of pro-apoptotic
genes in human fibroblasts [4]. Additionally, the lncRNAs
linc-RoR [37] and loc285194 [38] have been reported to
be post-transcriptional regulators in this pathway. In this
study, we have expanded this knowledge by identifying
and characterizing Pint,abona fide p53 transcriptional
target that acts as negative modulator of the p53 response.
We identified three isoforms of Pint, transcribed from
an intergenic region in the mouse chromosome 6. These
transcripts are likely to be alternatively spliced variants, as
they all share the 5’ sequences and are regulated by p53.
Indeed, Pint transcription is closely controlled by p53,
which specifically binds to three functional p53REs con-
tained inside the Pint g e n o m i cl o c u s .W h i l eo n eo ft h e
three p53REs is located at the promoter, the other two are
several kilobases downstream, and could function as tran-
scriptional enhancers, contributing to the fine regulation
of Pint levels upon p53 activation.
Pint levels are finely controlled by p53, but unlike many
other known lincRNAs [36], Pint is ubiquitously expressed.
Even in the absence of p53 activation, Pint is relatively
robust (see Additional file 1: Figure S2C). This suggests
that Pint plays a role independently of p53 activation by
DNA damage. In fact, inhibition of Pint in the absence of
DNA damage causes an arrest in cell proliferation, as
opposed to the effect of Pint overexpression. Furthermore,
even in the presence of DNA damage, most of the genes
found to be regulated by Pint are involved in cellular path-
ways not directly related to p53. This suggests that Pint is
necessary for regulation of normal cell growth and prolif-
eration, and in the presence of DNA damage, Pint a c t sa sa
negative regulator of cell cycle arrest and as a pro-survival
molecule, modulating the effect of p53 activation through a
negative autoregulatory mechanism.
Pint binds directly to PRC2, and is required for the tar-
geting of PRC2 to specific genes for H3K27 tri-methyla-
tion and repression. The association of PRC2 with the
promoter of these genes is lost when Pint is depleted
from the cells, resulting in their transcriptional induction.
Moreover, the biological effect of Pint depletion is
strongly enhanced by PRC2 downregulation, whereas
Pint overexpression has no effect in a PRC2 knockdown
background. These results suggest that Pint cooperates
with PRC2 in the repression of genes required for survi-
val and proliferation.
We found that of the total number of genes affected by
Pint inhibition, 39% were upregulated and 61% downregu-
lated upon Pint knockdown, suggesting that many Pint-
regulated genes are indirect targets of Pint-induced gene
repression Interestingly, the top functional terms of the
genes downregulated by Pint are related to transcription
regulation (transcription regulator activity, transcription
factor activity, and DNA binding). By contrast, Pint-upre-
gulated genes are mostly involved in functions related to
extranuclear components of signaling cascades such as
pattern binding and polysaccharide binding (see Addi-
tional file 1: Figure S4F,G). These data are consistent with
a model in which Pint modulates the targeting of PRC2 to
specific transcription regulators, affecting the gene-expres-
sion cascade at its top, and resulting in broad downstream
effects.
The precise mechanism by which Pint contributes to
PRC2 targeting to specific loci remains to be defined. One
possibility is that Pint binds to genomic sequences, either
by Crick-Watson base pairing or DNA-RNA-DNA triple
helical structures. The latter has been shown for other non-
coding RNAs, resulting in transcriptional repression in the
case of the dihydrofolate reductase gene, DHFR [39], or in
epigenetic silencing in the case of ribosomal genes [40].
Additionally, we cannot exclude the possibility that Pint
interacts with protein complexes other than PRC2,, acting
as an RNA scaffold that brings together additional factors
that may determine target specificity. In fact, this has been
shown for the lincRNA HOTAIR, which interacts with the
PRC2 and Lysine-specific demethylase 1 complexes [41].
We have identified the human PINT ortholog, which,
despite relatively low overall sequence homology, shows
several analogies with mouse lincRNA. Human PINT is
not only transcriptionally induced by p53, but it conserves
all three fully functional p53REs present in mouse. PINT
significantly correlates positively or negatively with the
same KEGG pathways that are affected by Pint knock-
down in mouse cells. Furthermore, similarly to the mouse
Pint, human PINT presents nuclear localization, and has
previously been reported to interact with PRC2 [10]. The
similarities between murine and human lincRNAs suggest
that their study could help infer the molecular principles
underlying lincRNA functions with low sequence depen-
dency. Intriguingly, PINT appears to be significantly
downregulated in primary colon tumors, and its overex-
pression in human tumor cells inhibits their proliferation.
These observations contradict what might be expected
based on a simplistic interpretation of the mouse in vitro
phenotype, and could reflect species-specific aspects of
cellular pathways and/or the known intrinsic biological
differences between mouse in vitro models and human
tumor cells [42].
Conclusions
In summary, we have identified a lincRNA, Pint,w h i c h
establishes a new connection between the tumor suppres-
sor p53 and epigenetic regulation by PRC2. Furthermore,
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ponent of the p53 barrier against cancer.
Materials and methods
Cell lines, p53 restoration, and DNA damage induction
Lung tumor-derived cell lines were derived from indivi-
dual tumors in KrasLA2/+;Trp53LSL/LSL Rosa26-
CreERT2 animals [43]. Sarcomas were isolated when they
formed in Trp53LSL/LSL Rosa26CreERT2 animals as
described previously [23]. p53
LSL/LSL MEFs were isolated
from embryos of the same mouse strain. For p53 restora-
tion, cultured tumor cell lines were incubated with 500
nM 4-hydroxytamoxifen (Sigma) for the indicated time
points, and p53
LSL/LSL MEFs were infected with Ade-
noCre or AdenoGFP virus for 24 hours (at the University
of Iowa) at a multiplicity of infection (MOI) of 5. NIH/
3T3 MEF cells were purchased from ATCC. The LKR
Lung tumor-derived cell line was isolated from individual
tumors from KrasLA2/+ mice. HTC116 p53
+/+ and p53
-/-
were kindly provided by Dr Vogelstein’s laboratory. For
DNA damage, cells were treated with 100 to 500 nM
doxorubicin hydrochloride (D1515; Sigma) or 385 μMo f
5-FU.
Promoter reporter assays and chromatin
immunoprecipitation
PINT genomic sequences (about 2,000 bp) flanking
p53REs were amplified from human and mouse genomic
DNA, and subcloned into pGL3-basic vector (Promega).
The TK-Renilla plasmid was used as normalizing con-
trol. Firefly and Renilla luciferase activities were mea-
sured using the dual luciferase reporter assay kit
(Promega) and a FLUOstar Optima luminometer (BMG
Labtech). ChIP experiments were performed as previously
described [44].
Rapid amplification of cDNA ends (RACE)
Using TRIzol reagent, total RNA was isolated from NIH/
3T3 MEFs treated with doxorubicin hydrochloride for 12
hours. cDNAs were then amplified, and PINT isoforms
were identified using the First Choice RLM-RACE Kit
(Ambion), and followed by DNA sequencing.
Stable cell line generation
For stable PINT overexpression, PINT was cloned into
the pBABE vector for retrovirus production, then NIH/
3T3 MEFs were infected and selected with 1.5 μg/ml of
puromycin for 72 h. For generation of Ezh2 shRNA and
stable control NIH/3T3 cells, shRNA lentiviral infection
was used as previously described [45].
qPCR primers and Antibodies
The qRT-PCR and ChIP-qPCR primer sequences and
antibodies used in this study are listed (see Additional
file 1: Supplemental methods).
siRNAs, anti-sense oligo transfection, and PINT transient
overexpression
All siRNAs and ASOs used in this study are listed (see
Additional file 1: Supplemental methods). All ASOs were
designed and provided by ISIS Pharmaceuticals. All were
20 nucleotides in length and were chemically modified with
phosphorothioate in the backbone, five 2’-O-methoxyethyl
residues at each terminus, and a central deoxynucleotide
region of 10 residues (5-10-5 gapmer). ASOs were synthe-
sized using an Applied Biosystems 380B automated DNA
synthesizer (PerkinElmer Life and Analytical Sciences-
Applied Biosystems), and purified as previously described
[24]. ASOs were selected from a larger panel of oligos,
based on the achieved PINT RNA inhibition and an
absence of toxicity. ASOs were used independently (ASO-1
and ASO-2) or as a pool (ASO-1 to ASO-4) (knockdown
levels for each ASO independently are shown; see Addi-
tional file 1: Figure S3A). In all cases, ASOs and siRNAs
were transfected at a total concentration of 100 nM with
Lipofectamine 2000 (Invitrogen) following the manufac-
turer’s instructions. For transient overexpression experi-
ments, PINT sequence was cloned into pcDNA3.
Microarray analysis
For gene-expression profiling, total RNA was extracted
and hybridized to an Affymetrix Mouse Genome 430 2.0
microarray. For human tissue samples, total RNA was
hybridized to Agilent SurePrint G3 8x60K microarrays.
Data normalization and analysis were performed with
GiTools [34] (for more information see (see Additional file
1: Supplemental methods)
Cell proliferation assays
For proliferation analysis, 2,000 cells were plated per
well in 96-well plates and assessed with a CellTiter96
Aqueous Non-Radioactive Cell Proliferation Assay
(MTS) Kit (Promega).
For clonogenicity assays, cells were transfected, plated at
10
3 to 2 × 10
3 cells per well of a six-well plate and grown
in normal medium for 10 days. Cells were then fixed and
stained with crystal violet. For soft agar colony formation
assays, 1 × 10
4 and 5 × 10
4 cells/ml were plated in a
volume of 1 ml 0.3% agar (Ref. 214220, C-35; DIFCO)
over 1 ml 0.5% agar base layers in each six-well plate. Cul-
tures were monitored for growth by viewing under an
inverted microscope. At the time of maximum colony for-
mation (7 to 21 days of culture), colonies were stained
with MTT (Sigma), and digital photgraphs were taken.
Apoptosis and cell cycle analyses
At 24 hours after transfection, 1 × 10
5 cells were plated
in 96-well white microplates, and treated for 24 hours
with 500 nM doxorubicin. Apoptosis was determined by
quantification with caspase-Glo 3/7 reagent (Promega)
using a FLUOstar Optima luminometer, and with annexin
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Apoptosis Detection Kit I (cat-559763; BD Biosciences).
For cell cycle analysis, cells were labeled for 3 hours with
bromodeoxyuridine (BrdU), and stained with propidium
iodide (PI) using a BrdU flow kit(BD Bioscience) and
sorted and quantified with a BD FACSCalibur flow cyt-
ometer (BD Biosciences). Data represent the mean ± SD
of a minimum of three biological replicates.
Human samples
Samples from patients with colorectal cancer (tumor and
normal tissue; see Additional file 8) were obtained by sur-
gical resection at the Municipal Hospital of Badalona,
Spain. Tumors were staged in accordance with the Ameri-
can Joint Cancer Committee (AJCC) criteria. The adjacent
normal tissue was obtained from areas 20 cm distant from
the tumor, and diagnosis of normal mucosa was confirmed
histologically. The work was carried out in compliance
with the Declaration of Helsinki, and all patients provided
signed informed consent.
Nuclear fractionation and fluorescence in situ
hybridization
Nuclear fractionation was performed as previously
described [3]. RNA FISH for PINT detection was per-
formed using a pool of 48 fluorescent probes purchased
from Stellaris Biosearch Technologies, following the man-
ufacturer’s protocol.
X-linked RNA immunoprecipitation and RNA pulldown
RNA immunoprecipitation was performed after formal-
dehyde crosslinking of cells, as described previously [3].
RNA pulldowns were performed as described previously
[28]. PRC2 was purchased from BPS Bioscience (catalo-
gue number 3m:51003)
Statistical analysis
Experimental data are represented as the mean ± SD of
a minimum of three biologic replicates and were com-
pared using Student’s t-test. Significant P-values are
indicated with asterisks as follows: *P <0 . 0 5 ,* * P <0 . 0 1 ,
and ***P < 0.001.
Accession numbers
Full-length sequences of PINT A, B and C have been
deposited in GenBank (accession numbers KC860257,
KC860259, KC860258 respectively). All primary data are
available at the Gene Expression Omnibus (GSE46272).
Additional material
Additional file 1: Supplemental materials and methods, and
supplementary figures with figure legends and PINT sequences.
Additional file 2: Table S1. p53 response elements (p53REs). found
in mouse and human PINT genomic loci.
Additional file 3: Table S2 Genes affected by Pint inhibition.
Additional file 4: Table S3 Predicted upstream regulators of genes
affected by Pint knockdown.
Additional file 5: Table S4 Genes affected by p53 inhibition.
Additional file 6: Table S5 Genes commonly affected by Pint and
p53 inhibition.
Additional file 7: Table S6 Genes regulated by Pint and bound by
Suz12 [31].
Additional file 8: Table S7 Information on the human samples used
in this study.
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